0001104659-23-014522.txt : 20230208 0001104659-23-014522.hdr.sgml : 20230208 20230208160516 ACCESSION NUMBER: 0001104659-23-014522 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20230208 DATE AS OF CHANGE: 20230208 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Calithera Biosciences, Inc. CENTRAL INDEX KEY: 0001496671 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 272366329 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-88349 FILM NUMBER: 23599060 BUSINESS ADDRESS: STREET 1: 343 OYSTER POINT BLVD #200 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-870-1000 MAIL ADDRESS: STREET 1: 343 OYSTER POINT BLVD #200 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: INCYTE CORP CENTRAL INDEX KEY: 0000879169 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 943136539 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 1801 AUGUSTINE CUT-OFF CITY: WILMINGTON STATE: DE ZIP: 19803 BUSINESS PHONE: 3024986700 MAIL ADDRESS: STREET 1: 1801 AUGUSTINE CUT-OFF CITY: WILMINGTON STATE: DE ZIP: 19803 FORMER COMPANY: FORMER CONFORMED NAME: INCYTE CORP DATE OF NAME CHANGE: 20030318 FORMER COMPANY: FORMER CONFORMED NAME: INCYTE GENOMICS INC DATE OF NAME CHANGE: 20000710 FORMER COMPANY: FORMER CONFORMED NAME: INCYTE PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930902 SC 13G/A 1 tm235824d1_sc13ga.htm SC 13G/A

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

SCHEDULE 13G

 

Under the Securities Exchange Act of 1934
(Amendment No. 1)*

 

Calithera Biosciences, Inc.

(Name of Issuer)

 

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

 

13089P101

(CUSIP Number)

 

January 13, 2023

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
¨  Rule 13d-1(b)
x  Rule 13d-1(c)
¨  Rule 13d-1(d)

 

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

 

CUSIP No. 13089P10113G (Amendment No. 1)Page 2 of 5 Pages

 

1.  

NAMES OF REPORTING PERSONS

 

Incyte Corporation

    
2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)
(a)    ¨
(b)    ¨		    
3.   SEC USE ONLY
 		    
4.   CITIZENSHIP OR PLACE OF ORGANIZATION
 
Delaware		    

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH		   5.   SOLE VOTING POWER
 
0
  6.   SHARED VOTING POWER
 
0
  7.   SOLE DISPOSITIVE POWER
 
0
  8.   SHARED DISPOSITIVE POWER
 
0

9.  

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

0

    
10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(see instructions)    ¨
 		    
11.  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

0%

    
12.  

TYPE OF REPORTING PERSON (see instructions)

 

CO

    

 

 

 

 

CUSIP No. 13089P10113G (Amendment No. 1)Page 3 of 5 Pages

 

Item 1(a) Name of Issuer:
   
  Calithera Biosciences, Inc.
   
Item 1(b) Address of Issuer’s Principal Executive Offices:
   
 

343 Oyster Point Blvd., Suite 200

South San Francisco, CA 94080

   
Item 2(a) Name of Person Filing:
   
  Incyte Corporation
   
Item 2(b) Address of the Principal Business Office or, if none, Residence:
   
  1801 Augustine Cut-Off, Wilmington, DE 19803
   
Item 2(c) Citizenship:
   
  Delaware
   
Item 2(d) Title of Class of Securities:
   
  common stock, par value $0.0001 per share (“Common Stock”)
   
Item 2(e) CUSIP Number:
   
  13089P101
   
Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
   
  Not applicable
   
Item 4. Ownership

 

  (a) Amount beneficially owned:  0 shares
   
  (b) Percent of class:  0%
   
  (c) Number of shares as to which the person has: 

 

  (i) Sole power to vote or to direct the vote:  0 shares
   
  (ii) Shared power to vote or to direct the vote:  0
   
  (iii) Sole power to dispose or to direct the disposition of:  0 shares
   
  (iv) Shared power to dispose or to direct the disposition of:  0

 

 

 

 

CUSIP No. 13089P10113G (Amendment No. 1)Page 4 of 5 Pages

 

Item 5.Ownership of Five Percent or Less of a Class.

 

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following x.

 

Item 6.Ownership of More than Five Percent on Behalf of Another Person.

 

Not applicable

 

Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

 

Not applicable

 

Item 8.Identification and Classification of Members of the Group.

 

Not applicable

 

Item 9.Notice of Dissolution of Group.

 

Not applicable

 

Item 10.Certification.

 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

 

 

 

 

CUSIP No. 13089P10113G (Amendment No. 1)Page 5 of 5 Pages

 

Signature

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: February 8, 2023  

 

  INCYTE CORPORATION
     
  By: /s/ Maria E. Pasquale
    Maria E. Pasquale
    Executive Vice President and
    General Counsel